Advancing science. Improving connections.

We focus our research and development efforts on rare (affecting fewer than 200K patients in the U.S.1) and near-rare (affecting fewer than one million patients) neuropsychiatric conditions.

Our lead product candidate, ZYN002 is a CBD gel currently being evaluated for Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD) in pediatric patients, 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Clinical Pipeline and Expected Milestones

Clinical Pipeline

Please click on disease name for more information.

     

 

Ongoing
Planned

 

Upcoming Milestones

These timelines are subject to change due to regulatory, clinical and other considerations.